Travere Therapeutics Inc is a biotechnology business based in the US. Travere Therapeutics shares (TVTX) are listed on the NASDAQ and all prices are listed in US Dollars. Travere Therapeutics employs 310 staff and has a trailing 12-month revenue of around $228.1 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $25.42 |
|---|---|
| 52-week range | $20.80 - $31.65 |
| 50-day moving average | $26.20 |
| 200-day moving average | $26.11 |
| Wall St. target price | $35.30 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.29 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $25.42 from 2022-10-03
| 1 week (2022-09-28) | 0.51% |
|---|---|
| 1 month (2022-09-02) | -6.65% |
| 3 months (2022-07-05) | 1.07% |
| 6 months (2022-04-04) | -12.34% |
| 1 year (2021-10-05) | 0.12% |
|---|---|
| 2 years (2020-10-05) | 26.09% |
| 3 years (2019-10-04) | 116.34% |
| 5 years (2017-10-04) | 3.59% |
| Revenue TTM | $228.1 million |
|---|---|
| Gross profit TTM | $220.7 million |
| Return on assets TTM | -15.1% |
| Return on equity TTM | -94.15% |
| Profit margin | -100.92% |
| Book value | $2.46 |
| Market capitalisation | $1.6 billion |
TTM: trailing 12 months
We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.
Travere Therapeutics's shares were split on a 1:9 basis on 8 November 2011. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.
Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $20.8 up to $31.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.5761. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).
Travere Therapeutics, Inc. , a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.